RS63608B1 - Pirimidinsko jedinjenje kao inhibitor jak kinaze - Google Patents

Pirimidinsko jedinjenje kao inhibitor jak kinaze

Info

Publication number
RS63608B1
RS63608B1 RS20220903A RSP20220903A RS63608B1 RS 63608 B1 RS63608 B1 RS 63608B1 RS 20220903 A RS20220903 A RS 20220903A RS P20220903 A RSP20220903 A RS P20220903A RS 63608 B1 RS63608 B1 RS 63608B1
Authority
RS
Serbia
Prior art keywords
kinase inhibitor
pyrimidine compound
jak kinase
jak
pyrimidine
Prior art date
Application number
RS20220903A
Other languages
English (en)
Inventor
Jennifer Kozak
Ryan Hudson
Gary E L Brandt
Robert Murray Mckinnell
Marta Dabros
Jerry Nzerem
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of RS63608B1 publication Critical patent/RS63608B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
RS20220903A 2017-10-27 2018-10-26 Pirimidinsko jedinjenje kao inhibitor jak kinaze RS63608B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
EP18801171.2A EP3672965B1 (en) 2017-10-27 2018-10-26 Pyrimidine compound as jak kinase inhibitor

Publications (1)

Publication Number Publication Date
RS63608B1 true RS63608B1 (sr) 2022-10-31

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220903A RS63608B1 (sr) 2017-10-27 2018-10-26 Pirimidinsko jedinjenje kao inhibitor jak kinaze

Country Status (37)

Country Link
US (7) US10308646B2 (sr)
EP (1) EP3672965B1 (sr)
JP (1) JP7218364B2 (sr)
KR (1) KR102613503B1 (sr)
CN (1) CN111247142B (sr)
AR (1) AR113803A1 (sr)
AU (1) AU2018354370B2 (sr)
BR (1) BR112020008015A2 (sr)
CA (1) CA3074034A1 (sr)
CL (1) CL2020001090A1 (sr)
CR (1) CR20200180A (sr)
CU (1) CU24671B1 (sr)
DK (1) DK3672965T3 (sr)
DO (1) DOP2020000083A (sr)
EA (1) EA202091016A1 (sr)
EC (1) ECSP20023795A (sr)
ES (1) ES2932526T3 (sr)
GE (1) GEP20227344B (sr)
HR (1) HRP20221221T1 (sr)
HU (1) HUE060401T2 (sr)
IL (1) IL274037B2 (sr)
LT (1) LT3672965T (sr)
MA (1) MA49956B1 (sr)
MD (1) MD3672965T2 (sr)
MX (1) MX2020004255A (sr)
NI (1) NI202000032A (sr)
PE (1) PE20201495A1 (sr)
PH (1) PH12020500528A1 (sr)
PL (1) PL3672965T3 (sr)
PT (1) PT3672965T (sr)
RS (1) RS63608B1 (sr)
SG (1) SG11202001706RA (sr)
SI (1) SI3672965T1 (sr)
TW (1) TWI789446B (sr)
UA (1) UA125130C2 (sr)
WO (1) WO2019084383A1 (sr)
ZA (1) ZA202001641B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7218364B2 (ja) 2017-10-27 2023-02-06 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのピリミジン化合物
CN115925705A (zh) * 2018-11-30 2023-04-07 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
CA3135383A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors
KR20230054682A (ko) * 2020-07-28 2023-04-25 아큐티스 바이오테라퓨틱스, 인크. Jak 저해제 및 라우레스-4를 함유하는 국소 제형
JP2023543670A (ja) * 2020-08-26 2023-10-18 ナロ・セラピューティクス Mycファミリー癌原遺伝子タンパク質のモジュレーター
EP4225438A1 (en) * 2020-10-08 2023-08-16 Icahn School of Medicine at Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2265452T3 (es) 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
EP1831216A2 (en) 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
WO2007059299A1 (en) 2005-11-16 2007-05-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2008016523A (es) 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (sr) * 2014-08-21 2018-03-31
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドHanmi Fine Chemical Co., Ltd. 高純度の(r)−9−[2−(ホスホノメトキシ)プロピル]アデニンの製造方法
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EA035226B1 (ru) 2016-04-28 2020-05-19 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пиримидиновые соединения в качестве ингибиторов jak киназы
JP7218364B2 (ja) * 2017-10-27 2023-02-06 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのピリミジン化合物
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
CA3135383A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors

Also Published As

Publication number Publication date
SG11202001706RA (en) 2020-03-30
US20220396573A1 (en) 2022-12-15
US10308646B2 (en) 2019-06-04
DOP2020000083A (es) 2020-08-15
US20240158389A1 (en) 2024-05-16
IL274037B1 (en) 2023-07-01
MX2020004255A (es) 2020-07-29
KR20200078517A (ko) 2020-07-01
AU2018354370B2 (en) 2023-04-27
US11420965B2 (en) 2022-08-23
PT3672965T (pt) 2022-09-29
HRP20221221T1 (hr) 2022-12-09
CA3074034A1 (en) 2019-05-02
LT3672965T (lt) 2022-10-10
AR113803A1 (es) 2020-06-10
IL274037A (en) 2020-06-30
MD3672965T2 (ro) 2022-12-31
PE20201495A1 (es) 2020-12-29
BR112020008015A2 (pt) 2020-10-27
JP7218364B2 (ja) 2023-02-06
TWI789446B (zh) 2023-01-11
WO2019084383A1 (en) 2019-05-02
KR102613503B1 (ko) 2023-12-13
IL274037B2 (en) 2023-11-01
MA49956A (fr) 2020-07-01
JP2021501151A (ja) 2021-01-14
US20200369660A1 (en) 2020-11-26
ECSP20023795A (es) 2020-06-30
MA49956B1 (fr) 2022-11-30
SI3672965T1 (sl) 2022-11-30
CU20200053A7 (es) 2021-03-11
US11814377B2 (en) 2023-11-14
DK3672965T3 (da) 2022-10-03
ES2932526T3 (es) 2023-01-20
CN111247142A (zh) 2020-06-05
CN111247142B (zh) 2022-12-02
TW201930304A (zh) 2019-08-01
EP3672965B1 (en) 2022-09-07
US20200140430A1 (en) 2020-05-07
EA202091016A1 (ru) 2020-07-17
PL3672965T3 (pl) 2023-01-16
UA125130C2 (uk) 2022-01-12
US10562894B2 (en) 2020-02-18
ZA202001641B (en) 2021-04-28
CL2020001090A1 (es) 2020-08-21
CU24671B1 (es) 2023-07-12
PH12020500528A1 (en) 2021-06-07
AU2018354370A1 (en) 2020-04-09
NI202000032A (es) 2020-10-09
EP3672965A1 (en) 2020-07-01
US20190241555A1 (en) 2019-08-08
HUE060401T2 (hu) 2023-02-28
US10988470B2 (en) 2021-04-27
US20190127364A1 (en) 2019-05-02
CR20200180A (es) 2020-08-12
GEP20227344B (en) 2022-01-25
US20210214349A1 (en) 2021-07-15
US10774080B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
ZA201807179B (en) Pyrimidine compounds as jak kinase inhibitors
ZA202000395B (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
HK1255921A1 (zh) 嘧啶化合物
IL274037A (en) A pyrimidine compound as a JAK kinase inhibitor
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
HK1246667A1 (zh) 作為jak抑制劑的2-(吡唑並吡啶-3-基)嘧啶衍生物
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
HUE056942T2 (hu) Pirimidin vegyület
EP3727387A4 (en) PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
GB201613945D0 (en) Compounds useful as kinase inhibitors